Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 3
1985 6
1986 2
1987 5
1988 3
1989 2
1990 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Indecainide compared with quinidine for chronic stable ventricular arrhythmias secondary to coronary artery disease or to cardiomyopathy.
Giardina EG, Zaim S, Saroff AL, Kirschenbaum M. Giardina EG, et al. Am J Cardiol. 1987 Sep 1;60(7):584-9. doi: 10.1016/0002-9149(87)90310-9. Am J Cardiol. 1987. PMID: 2442993 Clinical Trial.
At least 90% of episodes of ventricular tachycardia were suppressed in 4 of 7 patients taking indecainide and 1 of 4 taking quinidine. No adverse effects were observed in the 7 patients who responded to indecainide and the 4 who responded quinidine, resulting in sho …
At least 90% of episodes of ventricular tachycardia were suppressed in 4 of 7 patients taking indecainide and 1 of 4 taking quinidine …
Effect of indecainide in patients with left ventricular dysfunction.
Giardina EV, Saroff AL, Schneider M. Giardina EV, et al. Clin Pharmacol Ther. 1990 Nov;48(5):582-9. doi: 10.1038/clpt.1990.195. Clin Pharmacol Ther. 1990. PMID: 2225716 Clinical Trial.
Indecainide, a new antiarrhythmic agent classified as type Ic was evaluated in 11 patients with heart disease who had greater than or equal to 30 ventricular premature complexes/hour, moderate-to-marked left ventricular dysfunction, and mean ejection fraction 34% +/- 8%. P …
Indecainide, a new antiarrhythmic agent classified as type Ic was evaluated in 11 patients with heart disease who had greater than or …
Indecainide for treatment of ventricular ectopic depolarizations: efficacy, pharmacokinetics, hemodynamic effects and safety.
Salerno DM, Krejci J, Granrud G, Hodges M. Salerno DM, et al. J Am Coll Cardiol. 1988 Apr;11(4):843-50. doi: 10.1016/0735-1097(88)90221-5. J Am Coll Cardiol. 1988. PMID: 3351153 Free article. Clinical Trial.
The mean trough plasma level of indecainide on optimal dosage was 409 +/- 173 ng/ml and the mean plasma elimination half-life was 10.3 +/- 2.3 h (range 7.1 to 14.2). No adverse hemodynamic effects of indecainide were detected. Side effects during short-term therapy …
The mean trough plasma level of indecainide on optimal dosage was 409 +/- 173 ng/ml and the mean plasma elimination half-life was 10. …
Chronic dietary oncogenicity studies of indecainide in rats and mice.
Sandusky GE, Usher RW, Tamura RN. Sandusky GE, et al. Fundam Appl Toxicol. 1987 Oct;9(3):436-47. doi: 10.1016/0272-0590(87)90026-1. Fundam Appl Toxicol. 1987. PMID: 3692003
The incidence of benign and malignant tumors in the treated groups was not increased by treatment with indecainide. Survival of B6C3F1 mice was not significantly affected by exposure to indecainide. Mean body weight gain was slightly decreased throughout the study i …
The incidence of benign and malignant tumors in the treated groups was not increased by treatment with indecainide. Survival of B6C3F …
Indecainide: effects on arrhythmias, electrophysiology, and cardiovascular dynamics.
Holland DR, Lacefield WB, Gonzales CR, Johnston SR, Turk JA. Holland DR, et al. J Cardiovasc Pharmacol. 1989 Sep;14(3):454-61. J Cardiovasc Pharmacol. 1989. PMID: 2476626
The cardiovascular pharmacology of indecainide, a new class I antiarrhythmic agent, was studied in intact animals. ...Arrhythmias produced by prior (24 h) coronary artery occlusion were converted to 50% sinus rhythm by indecainide (100 micrograms/kg/min, i.v.) at 1. …
The cardiovascular pharmacology of indecainide, a new class I antiarrhythmic agent, was studied in intact animals. ...Arrhythmias pro …
Recent antiarrhythmic drugs.
Jaillon P, Drici M. Jaillon P, et al. Am J Cardiol. 1989 Dec 5;64(20):65J-69J. doi: 10.1016/0002-9149(89)91203-4. Am J Cardiol. 1989. PMID: 2688391 Review.
According to their effects on the recovery kinetics of the sodium ion channel, these drugs are classified into 3 groups: IA (intermediate--cibenzoline, pirmenol, hydroxy-3-S-dihydroquinidine, quinacainol); IB (fast--tocainide, moricizine); IC (slow--flecainide, encainide, propafe …
According to their effects on the recovery kinetics of the sodium ion channel, these drugs are classified into 3 groups: IA (intermediate--c …
Antiarrhythmic effects of oral indecainide in patients with ventricular tachyarrhythmias.
Macina G, Turitto G, Stavens C, Fontaine J, Hariman R, Ursell S, el-Sherif N. Macina G, et al. Clin Cardiol. 1987 Jun;10(6):357-61. doi: 10.1002/clc.4960100611. Clin Cardiol. 1987. PMID: 3594958 Free article.
Spontaneous arrhythmias were quantitated by 24-h Holter monitor before and during therapy with indecainide. Spontaneous VT was sustained in 4 patients and nonsustained in 7. ...Indecainide suppressed VPBs in a high percentage of patients, but was much less successfu …
Spontaneous arrhythmias were quantitated by 24-h Holter monitor before and during therapy with indecainide. Spontaneous VT was sustai …
Antiarrhythmic and hemodynamic evaluation of indecainide and procainamide in nonsustained ventricular tachycardia.
Pratt CM, Francis MJ, Seals AA, Zoghbi W, Young JB. Pratt CM, et al. Am J Cardiol. 1990 Jul 1;66(1):68-74. doi: 10.1016/0002-9149(90)90738-m. Am J Cardiol. 1990. PMID: 2193498 Clinical Trial.
Proarrhythmia developed in 3 of 15 (20%) of the indecainide patients, but in no procainamide patient. In those tolerating indecainide, long-term suppression of ventricular premature complexes (VPCs) and of runs of VT was more consistent than with procainamide. While …
Proarrhythmia developed in 3 of 15 (20%) of the indecainide patients, but in no procainamide patient. In those tolerating indecain …
Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissues.
Steinberg MI, Wiest SA. Steinberg MI, et al. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):614-21. doi: 10.1097/00005344-198407000-00010. J Cardiovasc Pharmacol. 1984. PMID: 6206315
No resting block was apparent in either tissue at normal resting membrane potential. Indecainide had only minimal effects on automaticity arising from normal or depolarized (barium) membrane potentials. Thus, indecainide is a potent class I local anesthetic antiarrh …
No resting block was apparent in either tissue at normal resting membrane potential. Indecainide had only minimal effects on automati …
Metabolism of the antiarrhythmic agent, indecainide, in rats, dogs, and monkeys.
Lindstrom TD, Lacefield WB, Whitaker GW. Lindstrom TD, et al. Drug Metab Dispos. 1984 Nov-Dec;12(6):691-7. Drug Metab Dispos. 1984. PMID: 6150817
The biotransformation of indecainide, a potent new antiarrhythmic agent, has been studied in rats and dogs. Indecainide was excreted in the urine primarily as the unchanged compound. ...
The biotransformation of indecainide, a potent new antiarrhythmic agent, has been studied in rats and dogs. Indecainide was ex …
23 results